IPL 512602

Drug Profile

IPL 512602

Alternative Names: AVE 0547; IPL 512,602

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 07 Feb 2017 Discontinued - Phase-II for Asthma in Russia, Ukraine, Eastern Europe, USA (PO)
  • 07 Feb 2017 Discontinued - Preclinical for Allergic rhinitis in North America (PO)
  • 29 Jan 2007 Inflazyme completes the phase IIb CAPSICS trial for Asthma in the US, Eastern Europe, Russia and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top